Navigation Links
ISG15: A novel therapeutic target to slow breast cancer cell motility
Date:1/11/2012

sions in breast cancer cells. Targeted knockdown of both ISG15 and UbcH8 resulted in reconstitution of the cytoskeletal architecture. Dr. Desai said "Disruption of cellular architecture is a hallmark of cancer. The ISG15 pathway is also elevated in a variety of tumors. Our results therefore reveal that the ISG15 pathway which is aberrantly elevated in tumors could disrupt cell architecture and contribute to breast cancer cell motility". "Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, our observations in breast cancer must hold true for many other tumors".

If ISG15 confers motility to tumor cells in vivo, as suggested in this manuscript, then Dr. Desai concludes that "strategies to decrease ISGylation could provide a therapeutic advantage for patients diagnosed with metastatic tumors overexpressing the ISG15 pathway".

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said that "these intriguing studies by Desai and colleagues suggests that modulation of the ISG15 pathway may provide future therapeutic targets for breast cancer and other metastatic tumors".


'/>"/>
Contact: Dr. Shyamal D. Desai
sdesai@lsuhsc.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover novel anti-viral immune pathway in the mosquito
2. Chinese herbal medicine may provide novel treatment for alcohol abuse
3. Autism may be linked to abnormal immune system characteristics and novel protein fragment
4. Novel device removes heavy metals from water
5. Barracuda babies: Novel study sheds light on early life of prolific predator
6. Scientist-novelist back with second book at cell biology meeting
7. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
8. New study identifies novel role for PEA-15 protein in cancer growth
9. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
10. Benefit of novel drug in breast cancer seen in blood within weeks
11. Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... DURHAM, N.C. -- By mimicking the way embryonic stem cells ... believe they have taken an important first step toward growing ... disease. In a series of experiments using mouse embryonic ... own design to fashion a three-dimensional "patch" made up of ...
... release is available in Spanish . , ... fruits, nuts, whole grains and fish- appear less likely to ... Navarra, published in the October issue of Archives of ... has been found to be lower in Mediterranean than Northern ...
... BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... a member of the Oracle® PartnerNetwork, is showcasing its ... being held at the Moscone Center in San Francisco ... the Oracle Identity Assurance Partner Alliance, BIO-key will provide ...
Cached Biology News:New strategy for mending broken hearts? 2Mediterranean diet associated with reduced risk of depression 2BIO-key(R) International to Exhibit at Oracle(R) OpenWorld 2BIO-key(R) International to Exhibit at Oracle(R) OpenWorld 3
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised ... molecular diagnostics industry. BCC Research reveals in its new report that the market drivers ... and a growing need for better diagnostics as part of a molecular diagnostics trend. ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... InferMed , s ... will augment ... s olutions suite   Elsevier , ... and services, announced today the acquisition of  InferMed , a ... company. InferMed,s Arezzo technology supports clinicians in choosing ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... SAN MATEO, Calif., July 22, 2011 NeurogesX, Inc. ... on developing novel pain management therapies, today announced that ... purchase agreement in connection with a private placement to ... standard closing conditions, is expected to receive approximately $20 ...
... RO, ROG; OTCQX: RHHBY) announced today that the cobas ... for use in colorectal cancer. The cobas ... of colorectal cancer tissue that are predictive of individual ... antibody therapies. "By quickly and reliably ...
... have created a molecular polyhedron, a ground-breaking assembly that ... and consumer products, including magnetic and optical materials. ... the journal Science , was conducted by researchers ... Molecular Design Institute and the University of Milan,s Department ...
Cached Biology Technology:NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 2KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 3Chemists create molecular polyhedron -- and potential to enhance industrial and consumer products 2
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Myeloid Marker (BM-1)...
Request Info...
Biology Products: